Innovative metal-sensitized spectrofluorimetric method for the simultaneous determination of resveratrol and doxorubicin in human plasma: A holistic sustainability appraisal

IF 4.1 Q1 CHEMISTRY, ANALYTICAL
Maha Mohammad Abdel-Monem , Mohamed I. Walash , Asmaa Kamal El-Deen
{"title":"Innovative metal-sensitized spectrofluorimetric method for the simultaneous determination of resveratrol and doxorubicin in human plasma: A holistic sustainability appraisal","authors":"Maha Mohammad Abdel-Monem ,&nbsp;Mohamed I. Walash ,&nbsp;Asmaa Kamal El-Deen","doi":"10.1016/j.talo.2025.100447","DOIUrl":null,"url":null,"abstract":"<div><div>The potential synergistic cardioprotective effects of resveratrol and doxorubicin combination have made precise analytical approaches necessary for determining their concentrations in human plasma. Herein, we propose a novel spectrofluorimetric method for the concurrent determination of resveratrol and doxorubicin in spiked human plasma using constant-wavelength synchronous fluorescence spectroscopy (CW-SFS) and fluorescence sensitization with metal chelating agent. By taking the advantage of synchronous scan mode, the CW-SFS can simultaneously scan the emission and excitation wavelengths with a fixed wavelength difference (Δλ = 80 nm), eliminating spectral interference and improving selectivity and sensitivity in the process. To further enhance sensitivity, the fluorescence sensitization method with a metal chelating agent was applied, where the fluorescence signal of both drugs is greatly amplified by adding Al<sup>3+</sup>and diluting with ethanol, improving the detection limits. The new approach shows low limits of detection (LODs) and quantification (LOQs), with excellent linearity (<em>R<sup>2</sup></em> &gt; 0.999) over a wide concentration range of 10–1000 and 5–700 ng/mL for doxorubicin and resveratrol, respectively. The method was successfully applied to determine both drugs in spiked human plasma along with a holistic sustainability assessment. This innovative analytical method has the potential to be used in therapeutic drug monitoring, thereby facilitating the optimization of doxorubicin and resveratrol combination therapy for enhanced outcomes in therapeutic drug monitoring.</div></div>","PeriodicalId":436,"journal":{"name":"Talanta Open","volume":"11 ","pages":"Article 100447"},"PeriodicalIF":4.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Talanta Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666831925000499","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0

Abstract

The potential synergistic cardioprotective effects of resveratrol and doxorubicin combination have made precise analytical approaches necessary for determining their concentrations in human plasma. Herein, we propose a novel spectrofluorimetric method for the concurrent determination of resveratrol and doxorubicin in spiked human plasma using constant-wavelength synchronous fluorescence spectroscopy (CW-SFS) and fluorescence sensitization with metal chelating agent. By taking the advantage of synchronous scan mode, the CW-SFS can simultaneously scan the emission and excitation wavelengths with a fixed wavelength difference (Δλ = 80 nm), eliminating spectral interference and improving selectivity and sensitivity in the process. To further enhance sensitivity, the fluorescence sensitization method with a metal chelating agent was applied, where the fluorescence signal of both drugs is greatly amplified by adding Al3+and diluting with ethanol, improving the detection limits. The new approach shows low limits of detection (LODs) and quantification (LOQs), with excellent linearity (R2 > 0.999) over a wide concentration range of 10–1000 and 5–700 ng/mL for doxorubicin and resveratrol, respectively. The method was successfully applied to determine both drugs in spiked human plasma along with a holistic sustainability assessment. This innovative analytical method has the potential to be used in therapeutic drug monitoring, thereby facilitating the optimization of doxorubicin and resveratrol combination therapy for enhanced outcomes in therapeutic drug monitoring.

Abstract Image

求助全文
约1分钟内获得全文 求助全文
来源期刊
Talanta Open
Talanta Open Chemistry-Analytical Chemistry
CiteScore
5.20
自引率
0.00%
发文量
86
审稿时长
49 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信